Skip to Content
Find More Like This
Return to Search

HIV-1 envelope glycoprotein

United States Patent

9,738,688
August 22, 2017
View the Complete Patent at the US Patent & Trademark Office
Lawrence Berkeley National Laboratory - Visit the Technology Transfer and Intellectual Property Management Department Website
The present application relates to novel HIV-1 envelope glycoproteins, which may be utilized as HIV-1 vaccine immunogens, and antigens for crystallization, electron microscopy and other biophysical, biochemical and immunological studies for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions, which are formulated into the vaccines of the present invention.
Caulfield; Michael (Fort Washington, PA), Cupo; Albert (Stamford, CT), Dean; Hansi (New York, NY), Hoffenberg; Simon (Hartsdale, NY), King; C. Richter (Washington, DC), Klasse; P. J. (New York, NY), Marozsan; Andre (Milford, CT), Moore; John P. (New York, NY), Sanders; Rogier W. (New York, NY), Ward; Andrew (San Diego, CA), Wilson; Ian (La Jolla, CA), Julien; Jean-Philippe (San Diego, CA)
INTERNATIONAL AIDS VACCINE INITIATIVE (New York, NY), THE SCRIPPS RESEARCH INSTITUTE (La Jolla, CA), CORNELL UNIVERSITY (Ithaca, NY)
14/ 072,209
20140212458
November 5, 2013
FEDERAL FUNDING LEGEND This invention was made with government support under Grant GM046192, No. AI082362 AI100663, AI036082, AI036214, RR017573 and RR0012000 awarded by the National Institutes of Health, and grant numbers DE-AC02-05CH11231 and DE-AC02-06CH11357 awarded by the U.S. Department of Energy. The government has certain rights in the invention.